Antibiotic-Induced Loss of Gut Microbiome Metabolic Output Correlates with Clinical Responses to CAR T-Cell Therapy

Investigators observed that prior exposure to broad-spectrum ABX with extended anerobic coverage like piperacillin-tazobactam and meropenem was associated with worsened anti-CD19 CAR-T therapy survival outcomes in large B cell lymphoma patients, compared to other ABX classes.